Johnson & Johnson (JNJ) Tops Q3 EPS by 6c; adjusts forecast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $266.17 -1.62%
Financial Fact:
Research and development expense: 2.18B
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Research and development expense: 2.18B
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.59, $0.06 better than the analyst estimate of $2.53. Revenue for the quarter came in at $25.4 billion versus the consensus estimate of $25.38 billion.
GUIDANCE:
Johnson & Johnson sees FY2026 EPS of $10.95-$11.05, versus the consensus of $11.08. Johnson & Johnson sees FY2026 revenue of $101-101.4 billion, versus the consensus of $101.4 billion.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
- American Financial Group (AFG) Tops Q3 EPS by 19c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
